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LAG-3 has been shown to act as an inhibitory molecule
involved in the regulation of T cell activation, proliferation
and homeostasis. Exhausted T cell populations that evolve
in the tumor microenvironment or during chronic viral
infections show coordinated expression of LAG-3 and PD-
1. LAG-3 is structurally related to CD4 and binds to
MHCII. Anti-LAG-3 antibodies have demonstrated precli-
nical efficacy in several disease models in particular when
combined with anti-PD-1 antibodies. Studies have pro-
posed that LAG-3 blockade is efficacious in both CD4+
and CD8+ T cells despite the lack of significant MHCII
levels on CD8+ T cell. In the present study, we evaluated if
anti-LAG-3 efficacy is dependent on the ability of the anti-
body to inhibit the binding of LAG-3 to MHCII.
We have compared in a series of in vitro assays the bio-
logical activity of two distinct anti-mouse LAG-3 antibo-
dies: C9B7W which does not block the LAG-3 – MHCII
interaction and an in-house generated antibody 28G10
that strongly blocks the interaction between LAG-3 and
MHCII. Biophysical characterization revealed that C9B7W
and 28G10 recognize distinct epitopes on LAG-3, there-
fore explaining the difference in LAG3-MHCII interrup-
tion. However, no differences were observed in T cell
activation assays between the two antibodies using TCR
transgenic CD4+ T cells. In addition, their ability to syner-
gize with an anti-PD-1 antibody was also comparable.
To understand if the overall enhancement in CD4+ T cell
activation by C9B7W and 28G10 was achieved through dif-
ferent mechanisms, we profiled gene expression in T cells
stimulated in the presence of anti-LAG-3 antibodies. No
significant difference was found between the two antibo-
dies. Consistent with this observation, we did not see an
additive effect of C9B7W and 28G10 when used together
in vitro. Neither antibody demonstrated a significant effect
on the activity of TCR transgenic CD8+ T cells in in vitro
functional assays.
Furthermore, the two antibodies demonstrated com-
parable anti-tumor efficacy in in vivo syngeneic tumor
models when dosed in combination with anti-PD-1.
In conclusion, our studies demonstrate that the activity
of LAG-3-targeting antibodies is not associated with their
ability to disrupt LAG-3-MHCII interaction. This would
suggest that anti-LAG-3 antibodies should enhance both
CD4+ and CD8+ T cell function. Case in contrast, our in
vitro data demonstrates that LAG-3 targeting augments the
activation of CD4+ T cells significantly more than CD8+
T cells.
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